Abstract: Over the past two decades, there has been lot of interest in the use of liposomes as lipid-based biocompatible carriers for drugs administered by the intravesical route. The lipidic bilayer structure of liposomes facilitates their adherence to the apical membrane surface of luminal cells in the bladder, and their vesicular shape allows them to co-opt the endocytosis machinery for bladder uptake after instillation. Liposomes have been shown to enhance the penetration of both water-soluble and insoluble drugs, toxins, and oligonucleotides across the bladder epithelium. Empty liposomes composed entirely of the endogenous phospholipid, sphingomyelin, could counter mucosal inflammation and promote wound healing in patients suffering from interstitial cystitis. Recent clinical studies have tested multilamellar liposomes composed entirely of sphingomyelin as a novel intravesical therapy for interstitial cystitis. In addition, liposomes have been used as a delivery platform for the instillation of botulinum toxin in overactive bladder patients. The present review discusses the properties of liposomes that are important for their intrinsic therapeutic effect, summarizes the recently completed clinical studies with intravesical liposomes and covers the latest developments in this field.
Introduction
Liposomes are self-assembled vesicles of curved lipid bilayers surrounding an aqueous core (Fig. 1) . The main constituents of liposomes are phospholipids, which are amphiphilic molecules, containing the water-soluble phosphate head group and a hydrophobic lipid chain, which allow them to self-seal as vesicles.
Importantly, phospholipids are also one of the primary constituents of all cellular membranes, and their metabolites function as secondary signal transducers in cells. 1 Some of the most common phospholipids are the choline-phosphatides, such as sphingomyelin and phosphatidylcholine, 1 where the former is found in high concentrations in myelin sheath encasing the nerve fibers. At the subcellular level, phospholipids act as emulsifiers, which allow lipids and fluids to disperse evenly in cytoplasm, which facilitates efficient transport across cell compartments.
Over the past few decades, liposomes have been the subject of intense research as ideal models for biological cell membranes, as well as efficient carriers for drugs, diagnostics, vaccines and other bioactive agents. 2 However, the application of liposomes in urology has lagged behind other fields. Liposomes composed entirely of phospholipids have been previously shown to enhance healing and regeneration of the ocular surface on topical application. 3, 4 Healing properties of liposomes were shown in the treatment of keratitis, corneal transplant rejection, uveitis and endophthalmitis. 5 As liposomes were able to pass the tolerability threshold for ocular surfaces, their instillation into the human bladder as a potential topical therapeutic agent for several intractable urological disease, such as IC, carried low risk. The present review summarizes recent clinical studies that showed the therapeutic potential of liposomes as a drug, and discusses the basic research that supports the use of liposomes as a drug and a delivery platform in urology.
Prevalence and pathophysiology of interstitial cystitis
IC is an idiopathic condition characterized by intermittent flares of frequent and urgent voiding and pain in the bladder and urethra for which there is no effective treatment. The RAND Interstitial Cystitis Epidemiology telephone survey estimated that up to 6.5% of women in the USA might be able to meet the symptom criteria for IC. 6 The prevalence rate of IC based on clinical diagnosis can vary from 0.3% to 2% of the population in different regions of the world. 7 Hunner's lesion is noted in 10% of the IC patient population, but the urothelium barrier is considered to be disrupted in the majority of patients. 8 
Role of inflammation
Animal studies have consistently shown that inflammatory conditions of the bladder can produce the cardinal IC symptom of suprapubic or pelvic pain. [9] [10] [11] Patients experience severe pain with a full bladder, which is reduced on voiding of urine or its alkalization. 12 These characteristics of IC pain implicate the role of impaired epithelial barrier in IC patients. 13 The disruption in barrier function is likely to cause an ingress of urinary constituents into the lamina propria and underlying muscle layers, resulting in inflammation, and suprapubic and lower back pain from afferent nerve sensitization. 14 Increased expression of the extrinsic apoptotic pathway proteins, Fas, and of cleaved caspase-8 and caspase-3 enzymes in the bladder of IC patients is linked to the impaired integrity of the epithelial barrier. 15 The role of mitochondrial oxidative stress is also suspected in increased apoptosis that ultimately compromises the epithelial barrier. Gene expression studies on bladder biopsies also supported the role of inflammation in IC patients. 16 A recent study reported that infiltration of CXCR3-positive plasma cells is a characteristic feature of IC marked by Hunner's lesions. 17 
Current status of IC treatment
The acceptance for the role of disrupted barrier in pathophysiology of IC motivated the search for drugs that augment the regeneration of the epithelial barrier that are now approved as IC treatment. 15 Daily oral administration of pentosan polysulfate seeks to replenish the damaged glycoaminoglycan layer of IC patients. 18, 19 However, a double-blind study of 368 IC patients failed to find a significant symptom improvement with pentosan polysulfate. 20 Instead of oral drugs for augmenting the urothelium barrier of IC patients, certain countries have approved the intravesical administration of hyaluronic acid with modest efficacy. 21 NGF is considered a key molecular mediator of pain and urinary symptoms of IC patients, 8 which makes it a drug target for IC. However, a recent double-blind study of fully human monoclonal antibody directed against NGF found that it does not provide pain relief to IC patients. 22 The effectiveness of current treatments is limited due to various reasons described in detail in a recent review. 23 Deficiencies in the current treatments of IC are motivating the search efforts for new therapeutic agents, such as liposomes, which are being reviewed here.
Liposomes as a therapeutic agent
Since topical application of liposomes was able to enhance healing and regeneration in the eye, a similar topical application in the bladder through the intravesical route was explored to augment the urothelium barrier in IC. The efficacy of intravesical liposomes composed entirely of sphingomyelin was assessed in a rat model of cystitis relative to FDA approved therapies of dimethyl sulphoxide and pentosane polysulfate. 24 Cystometry studies showed that infusion of liposomes mixed with potassium chloride was able to significantly reduce the urinary frequency increased by potassium chloride after protamine sulfate injury, compared with acute infusion of pentosan polysulfate or dimethyl sulphoxide. 24 Findings were consistent with the ability of liposomes to act as a physical coating on the injured luminal surface of the bladder, and repair the protamine sulfate-induced disruption in the urothelium (Fig. 2) . 25 Furthermore, histological studies on bladders harvested at the end of cystometry showed that liposomes enhanced the healing of bladder injury. Similar findings of wound healing and epithelial repair were also noted in IC patients with Hunner's lesions. 26, 27 Clinical trial on empty liposomes Chuang et al. was first to translate the findings obtained from rodent models of bladder injury to the clinic. 28 The concentration of lipid in the reconstituted liposomes for clinical study was kept the same as in the study on rodents by reconstituting freeze-dried sphingomyelin liposomes (80 mg) in 40 mL of distilled water just before the instillation in 24 IC/PBS patients. Diagnosis of IC/PBS was based on a 6-month or longer history of the following symptoms: 10 or more daily urinary voids, average voided volume (50-200 cc) , nocturia (at least once per night), a suprapubic bladder pain score equal to or >1 (on a 0-5 pain scale) and urgency (at least 1 on a 0-5 urgency scale). Urinary tract infection in enrolled patients was ruled out by negative urine cytology and culture. Cystoscopy was carried out on enrolled patients to rule out any other pathological condition.
IC/PBS patients were recruited to an open-label prospective study to receive either a once a week instillation of liposomes for 4 weeks or receive three times daily oral therapy of pentosan polysulfate (100 mg) for 4 weeks. Patients were monitored closely for adverse events and urinary function including gross hematuria, urinary retention, urgency, frequency, and/or signs/symptoms of infection.
In order to assess the clinical safety and efficacy of sphingomyelin liposomes, 10 possible responses were collected at baseline and at week 4 from patients enrolled in the two treatment arms. Liposomes significantly decreased the urinary frequency and nocturia of IC/PBS patients. Efficacy of intravesical liposomes was comparable with the oral treatment of pentosan polysulfate. The most profound change after liposome treatment was observed in urgency along with statistically significant decreases in pain, urgency and the O'LearySant symptom score.
In a subsequent study, Chuang et al. assessed the effect of increased treatment frequency with liposomes in 17 IC/PBS patients. 29 A total of 12 patients were given four once a week instillations, and the remaining five patients were given twice a week instillations of liposomes in the same volume for 4 weeks. Both once a week and twice a week instillations were well tolerated by the patients. O'Leary-Sant Symptom/ Problem score, O'Leary-Sant total score, and pain score were improved from baseline in both treatment arms at the follow up of week 4 and 8. None of the dose regimens were associated with any incidence of urinary incontinence, retention, or unanticipated adverse changes.
Effect of liposomes on ulcers in bladder
Cystoscopic pictures shown for a single patient before and after 4 weeks of liposomes instillation by Chuang et al. suggested a wound healing effect of liposomes on bladder ulcers in IC patients. 28 Clinical findings reported by Chuang et al. were corroborated by findings reported by Peters et al. from a recently concluded open-label, single treatment arm study on 14 IC/PBS patients diagnosed by NIDDK criteria, who were refractory to at least one pharmacotherapy. 26, 27 Recruited IC/BPS patients were women of childbearing age without a history of bilateral tubal ligation or of postmenopausal status for at least 1 year, and agreed to use an acceptable means of contraception during the entire 4-week course of therapy and 1 week thereafter. The dose of sphingomyelin liposomes was the same as that used by Chuang et al. once a week for 4 weeks ( Table 1) .
Cystoscopy carried out at baseline and at 8 weeks posttreatment confirmed the morphological changes on bladder ulcer caused by liposome instillation. 26, 27 Clinical outcomes were assessed at 1, 4 and 8 weeks after the last instillation for a total of 12 weeks from the commencement of treatment. The scores for urgency and interstitial cystitis symptom/pain index scores showed significant improvement at both 4 and 8 weeks post-treatment, but pain scores only showed significant improvement at 4 weeks post-treatment and not at 8 weeks. Global response assessment showed slight improvement at both time-points. Overall, 4-weekly treatment of liposomes significantly decreased the pain, urgency and symptom scores in IC/PBS patients. 26 
Mechanism of action?
Based on the available evidence, the mechanism of action for empty liposomes in the bladder likely involves a combination of a physical coating on the urothelium, and also a drug-like action that promotes repair and regeneration of the bladder lining. 25, 27 Findings in an animal model of protamine sulfate injury were supported by the increased proliferation of rat urothelium cells in primary culture after application of sphingomyelin liposomes, and by the liposomes-mediated reduction of cell death after brief exposure to toxic acrolein. 30 Findings from cultured cells exposed to acrolein were recapitulated after intravesical administration of liposomes in rat bladder injured by acute exposure to protamine sulfate. 25, 31, 32 The drug-like action of sphingomyelin liposomes is inextricably linked to the intrinsic anti-inflammatory effect of sphingomyelin, 31 which is the primary constituent of the liposomes used so far for IC [26] [27] [28] and OAB patients. [33] [34] [35] Sphingomyelin is also a component of a regular diet, as it is a nutritional component of egg yolk and milk. The anti-inflammatory effect of orally administered sphingomyelin was evident from the depletion of macrophages and the reduced number of CD4 + T cells in mesenteric lymph nodes. 36, 37 The antiinflammatory effect of sphingomyelin has been reported from mouse models, 37 and from patients with inflammatory bowel disease. 36, 38 Orally-consumed sphingomyelin is hydrolyzed to ceramide and sphingosine throughout the intestinal tract, 39 and a similar metabolism was presumed for the sphingomyelin liposomes instilled in the bladder. Ceramide, sphingosine and sphingosine-1 phosphate are important signaling intermediates of apoptosis and cell proliferation. 1 Clinical studies have localized the presence of the key enzyme responsible for the metabolic degradation of sphingomyelin, called sphingomyelinase, in the urothelium. 40 However, the serum levels of sphingomyelin or its metabolites remain unaltered in rats after intravesical administration, suggesting either limited metabolism of instilled sphingomyelin liposomes in the bladder tissue or reduced serum uptake of its metabolic products. 41 Anti-inflammatory effect of sphingomyelin Nuclear receptor superfamily PPAR are considered to play an important role in the anti-inflammatory effect of sphingomyelin. PPAR are endogenously controlled molecular switches for sensing the intracellular nutrient concentrations, and for regulating the gene expression in maintenance of both metabolic and immune homeostasis. 42 PPAR-c is ubiquitously expressed in the urothelium and CD4 + T cells, where its activation is likely to attenuate the inflammatory responses through reduced adipocytokine signaling. 43 PPAR-c regulates the differentiation of CD4 + T cells into at least four functionally distinct subsets referred to as Th1, Th2, Th17 and Treg. Functionally, Th1 and Th17 subsets are linked to an increased risk of autoimmune disorders, whereas Treg cells can attenuate inflammatory and immune-mediated diseases. 36 Based on studies involving wild-type and PPAR-c knockout mice, the anti-inflammatory effect of sphingomyelin is enhanced by PPAR-c expressed in the epithelial and immune cells. 42 The patterns of genes upregulated by sphingomyelin are chemokines and chemokine receptors expressed in epithelial cells, and those involved in cell trafficking (Ccl19, Ccl11, Ccl20, Cxcl9, Cxcl11), genes involved in CD4 + T cell differentiation and fate, including Th1 (interferon-c), Th17 (IL-17 and IL-23), Th2 (IL-4, IL-13, IL-13R) and Treg (IL-10R). The upregulation of genes in the Th2 differentiation pathway (IL-4, IL-13, IL-13R) and Treg-related genes, such as IL- 10R, is in line with the PPAR-c-dependent anti-inflammatory effect of sphingomyelin. However, changes in Th1, Th17, chemokines and chemokine receptors suggest that sphingomyelin can also modulate immunostimulatory and proinflammatory pathways. 36 Hence, further research is required to resolve the mechanism of its anti-inflammatory effect.
The anti-apoptotic effect of sphingomyelin could also play a role in drug-like action of sphingomyelin liposomes, as increased expression of apoptosis markers is reported in the bladder of IC patients, which could be linked to the mitochondrial oxidative stress. 15 PPAR-a promotes the transport of long-chain fatty acids into the mitochondria that in turn stimulates the beta-oxidative degradation of fatty acids by the carnitine O-palmitoyltransferase I system. As sphingomyelin is a nutrient that can be transported to mitochondria, the sphingomyelin liposomes instilled in the bladder can ride the endogenous lipid transport as a nutrient to mitochondria. In a PPAR-c-dependent manner, sphingomyelin can suppress the expression of apoptosis mediators, Fasl; inflammatory signaling intermediates, such as Myd88 and DOCK2; and transcriptional regulators, such as nuclear factor erythroid 2-related factor 1, nuclear factor related to kappa-B-binding protein NFRjB, and signal transducer and activator of transcription 3. Sphingomyelin can also inhibit phospholipase A2, which generates prostaglandin substrate from membrane lipids. 44 
Drugs entrapped in liposomes
The unique structure of liposomes can also be leveraged for entrapping the water-soluble drugs in the core and water-insoluble drugs in the bilayer (Fig. 1 ) in order to afford stability in hostile environment of bladder in terms of pH and ionic strength, controllable release kinetics, biocompatibility and biodistribution. Liposomes can be customized by altering the lipid composition to have varied sizes, rigidities and biological properties. We and others have investigated the liposomes as an intravesical delivery platform for water insoluble drugs, such as tacrolimus, 45, 46 capsaicin 47, 48 and water-soluble botulinum toxin. 28 An intravesical drug delivery platform is necessitated because of the poor permeability properties of the apical membrane and tight junctions of the urothelium towards drugs instilled in the bladder. Passive diffusion is one mode of bladder uptake across the urothelium for instilled drugs, but for it to happen, drugs must have high potency and possess appropriate physicochemical properties. These properties include low molecular weight (<400 Da), water/octanol partition coefficient in the range of 1-3 and a low melting point. All these requirements mean that the number of therapeutic drugs suitable for intravesical drug delivery are limited. Several strategies have been introduced that range from using penetration enhancers to temporarily compromise the barrier function in order to assist drug penetration. 49, 50 Drugs with large molecular weight, such as tacrolimus and botulinum toxin, face a challenge in passive diffusion across intact urothelium, 51, 52 but not across the injured urothelium of hemorrhagic cystitis. 53 Drugs can be actively or passively loaded into the liposomes. Liposomes are known to enhance penetration of drugs across the urothelium, but the mechanistic processes for this penetration enhancement is not completely known. 54 A study carried out with radiolabeled sphingomyelin liposomes showed deeper penetration of instilled radioactive label in the rat bladder, which might indicate deeper diffusion of the fatty acids carrying the radioactive carbon in sphingomyelin. 55 Effectiveness of the liposomal formulations have been shown in intravesical delivery of molecules ranging from low molecular weight drugs to macromolecular peptides and proteins.
Liposome + toxin
Liposome mediated transport of botulinum toxin BoNT-A into the urothelium was confirmed by the immunohistochemical detection of the proteolysis of synaptosomal-associated protein SNAP-25, which is involved in neuoexocytosis of neurotransmitters. 28 Liposomes limited the BoNT-A delivery to the mucosa and restricted the delivery to detrusor muscle, which could potentially reduce the risk of incomplete bladder emptying in patients. The lack of efficacy of BoNT-A instillation in the absence of liposomes could be related to the catabolic action of urinary proteases and proteinases on BoNT-A protein, dilution of BoNT-A in urine or poor uptake of the BoNT-A across the urothelium. 56 Encouraged by the animal results, Kuo et al. tested the clinical efficacy of liposomal delivery of BoNT in 24 OAB patients in a randomized double-blind parallel controlled trial. 34 The dose of empty liposomes was the same as used earlier in patients by Chuang et al., and empty liposomes were complexed with 200 IU of BoNT-A. 28 Enrolled patients either received saline or liposome complexed with BoNT-A, which was held in the bladder for 60 min. Patients were allowed to drink water and distend their bladders for another 30 min. Instillation of BoNT-A with liposomes significantly decreased the 3-day voiding frequency from baseline with a median decrease of 6.5 voiding episodes from baseline. In contrast, saline instilled patients had no change from baseline. A significant decrease was also noted in urgency episodes, but not in urgency urinary incontinence episodes. There were no reports of large PVR, urinary retention or UTI in treated patients during the follow-up period. Liposomes are a suitable intravesical delivery platform for potent toxins, as reviewed here. 57 
Liposomal tacrolimus
Hemorrhagic cystitis is a rare and potentially fatal disease that results from damage to the bladder transitional epithelium and blood vessels by specific chemotherapeutic agents and/or pelvic radiation therapy. Liposomes formulated with tacrolimus were recently tested as a potential treatment, where single-dose application significantly reduced the inflammation and voiding changes associated with chemotherapy-induced hemorrhagic cystitis. 45 Successful delivery of tacrolimus in the bladder also decreased the prostaglandin EP4 receptor expression in the urothelium, and infiltration of inflammatory cells in the suburothelium region. Increased bladder tissue and urine levels of PGE2 and IL-2 were also suppressed by liposomal tacrolimus.
Blood analysis of treated rats showed that systemic levels of tacrolimus were below the detection limit of the (<1.5 ng/ mL) clinically approved assay for tacrolimus. 46 Liposomal tacrolimus also showed promise in reducing inflammation and improving the voiding outcomes in a recent study on rat model of radiation cystitis. 58 Studies showed that bladder instillation of liposomal tacrolimus is a promising treatment for hemorrhagic cystitis without the risks associated with the systemic distribution of tacrolimus. A recent case report described the intravesical administration of an intravenous formulation of tacrolimus as proof of principle for the efficacious intravesical use of tacrolimus for hemorrhagic cystitis. 53 
Liposomes + nucleic acids
Liposomes have been used to improve the inefficient uptake of negatively-charged nucleic acids by cells. 59 Studies show that complexation of synthetic nucleic acids with liposomes also increases their bladder uptake. 54, 59 As shown in Figure 2 , liposomes rely on endocytosis to improve the bladder uptake of oligonucleotide 54 and small interfering RNA, siRNA-loaded liposomes in the healthy bladder wall, 59 which could downregulate the expression of NGF 54 and pannexin, respectively.
59
These two target proteins have pathophysiological relevance in voiding dysfunctions, such as IC/PBS and urinary tract infection. In order to show functional efficacy of oligonucleotide and siRNA, NGF and pannexin overexpression in the bladder was induced by temporary exposure to acetic acid and lipopolysaccharide, respectively. 59 Animals were pretreated with ODN 54 and siRNA 59 before the exposure to insults (acetic acid and lipopolysaccharide), and the treatment efficacy was confirmed by functional and molecular end-points. Liposomes can improve the bladder uptake of nucleic acids. 60 
Endocytosis of liposomes in the bladder
Bladder uptake of instilled liposomes was recently investigated by several techniques, including flow cytometry, confocal and electron microscopy. 30, 58 Confocal microscopy showed that fluorescently-labeled liposomes are taken up by cultured urothelium cells in a temperature/energy-dependent manner. Cellular uptake of sphingomyelin liposomes was inhibited when cells were incubated at 4°C. Fluorescence imaging allowed the visualization of liposomes in the bladder, but the interactions between the urothelium barrier and liposomes are not easy to probe, because the nanoscale nature of these interactions means they are below the resolution limit of fluorescence microscopy techniques, such as confocal laser scanning microscopy and two-photon microscopy. 61 Nevertheless, fluorescent-labeled liposomes could help visualize the total penetration depth in the bladder, by relying on the assumption that fluorescent markers are still associated with the liposomal vesicles.
Ultrastructural studies with transmission electron microscopy using colloidal gold as a probe confirmed the results of confocal microscopy. 58 Flow cytometry analysis using inhibitors of caveloe-and clathrin-mediated endocytosis at 37°C showed that the uptake of liposomes by urothelium cells occurs through clathrin-mediated endocytosis. The physical shape of liposomes mimics vesicles, which can allow them to co-opt the endocytosis machinery of umbrella cells for the bladder uptake, because endocytosis of membrane vesicles plays a critical role in the dramatic morphological changes occurring in the apical surface of the urothelium during the micturition cycle. 62 Endocytosis of instilled liposomes in the bladder likely involves adherence followed by fusion or endocytosis into the umbrella cells. Previous studies showed that binding of large multilamellar liposomes to the urothelium was stronger compared with sonicated small-size liposomes. 63, 64 For many decades, the only tool capable of imaging below the Abbe's diffraction limit was EM. However, sample preparation in EM tends to alter the physiology of the urothelium during chemical treatments. EM studies require an extensive sample preparation for embedding and sectioning, which can have adverse effects on the sample integrity. Freeze fracture techniques demand laborious sample preparation, and the results can be quite difficult to interpret, because replicas of the original sample are being examined and not the sample itself. Also, qualitative and quantitative determinations in these studies are rather difficult.
Transition temperature of lipids and bladder uptake
The interactions of liposomes with the urothelium are considered to be influenced by the thermodynamic state of the liposomal bilayers. As the thermodynamic state is influenced by intrinsic characteristics of lipid, it is inferred that the liposome composition can have a huge influence on bladder uptake. Amphipathic molecules, such as sphingomyelin, undergo a thermotropic phase transition at 40°C, which is much lower than their melting point (Fig. 3) . The encapsulation efficiency of liposomes is generally higher at a higher transition temperature. Drugs encapsulated in liposomes with a high-phase transition temperature are generally released slowly, as liposomes tend to fuse with each other in order to reduce their surface tension, resulting in gradual payload release over time. 65, 66 Transition temperature depends on the length and degree of unsaturation in FA chains. The FA chains of sphingomyelin varies with the dietary source with 86.6% C16, 3.0% C22 and 3.0% C24 FA in egg yolk, and 23.4% C16, 18.2% C22, 30.0% C23 and 17.7% C24 FA in milk. The transition temperature is influenced by the nature of the phosphate group in the phospholipid, and ionic strength of the aqueous medium. Amphoteric and cationic liposomes, which have phase transition temperature below or near the body temperature, have higher permeability in epithelial cells compared with the anionic liposomal formulations. 67 Possible mechanisms include increased transcellular and paracellular transport after the opening of tight junctions.
The lipid bilayers can exist in a "gel state," characterized by rigid bilayers or a "liquid crystalline" state, where bilayers are relatively flexible and accommodating. For optimum drug delivery, a liquid crystalline state of phospholipid bilayers that can be either deformable or non-deformable is desired. A large number of studies associate non-deformable liposomes with topical drug delivery. Deformable liposomes contain other additives that yield deformability or elasticity to the liposomal bilayers.
Manufacture of liposomes for intravesical administration
A detailed review for the different preparation methods, characterization and properties of liposomes can be found elsewhere. 68 Several methods are available to prepare sterile and pyrogen-free liposomes including sonication, reverse phase evaporation, 69 microfluidization, 70 solvent dispersion and extrusion. In recent years, the approach of proliposomes has been gaining ground to achieve the desirable pharmaceutical attributes in the finished product given to patients. 71 Proliposomes can be of two types: particulate-based proliposomes comprise soluble, free-flowing carrier particles coated with phospholipids; whereas alcohol-based proliposomes comprise a concentrated alcoholic solution of phospholipids. Both these types of proliposomes generate liposomes on hydration as a result of increased surface area of the dried lipid film. A new method for manufacturing proliposomes is rapidly gaining interest, 72 which makes proliposomes of narrow size distribution (Fig. 4) by lyophilization (freeze drying) of monophasic solution of lipids and drugs. 73 An isotropic monophase solution is achieved by dissolving lipids and drug mixture in TBA/ water cosolvent systems. The resulting solution is then lyophilized after sterilization by filtration through 0.2-micron pores.
Physiochemical properties of TBA include high vapor pressure (4.1 kPa at 20°C), high melting point (24°C), low toxicity and miscibility in all proportions with water. Inclusion of TBA in the monophasic solution allows the formation of relatively large needle-shaped crystals during the freezing stage. The shape and size of the ice crystal is critical in the sublimation of ice during the freeze drying process. 74 The ratio of lipid and TBA is the key factor affecting the size and the polydispersity of liposome preparation.
The lyophilized product spontaneously forms multilamellar liposomes on hydration. 75 The freeze-drying process removes water and TBA, and only leaves dried proliposomes in the vial (Fig. 4) . As TBA is a toxic impurity, regulatory agencies have established its tolerable limits in the finished liposome product. Gas chromatography is a simple, sensitive, reliable and reproducible method for TBA quantitation. 76 A cross-linked dimethylpolysiloxane capillary column connected to a flame ionization detector is used to determine the residual TBA in the lyophilized liposomes, using sec-butanol as the internal standard.
Stability
Liposomes being a colloidal system are inherently unstable. The stability of liposomes can be characterized by the interrelated aspects of physical, chemical, colloidal and biological parameters. Physical stability refers to the likely changes in the liposome integrity as a result of physical factors, such as temperature increase, shear and vibration, which can potentially increase the lipid bilayer fluidity and also increase the leakage of encapsulated drug. Liposomes for clinical use are tested for these parameters. Liposomes with a rigid bilayer tend to be more physically stable.
Chemical stability refers to the ability of liposomes to maintain the level of encapsulation efficiency without changes in solution chemistry, such as pH, electrolyte composition and oxidation. Lipids with unsaturated fatty acids are more vulnerable to oxidation, whereas both saturated and unsaturated lipids are subject to acyl ester bond hydrolysis to form lysolipids and free fatty acids. Lyophilization of liposomes reduces the water content of stored liposomes to reduce the concern of hydrolysis. Chemical stability of empty liposomes and drug-loaded liposomes are taken up separately to assess the possible degradation or other reaction processes unique to the liposomes. Chemical degradation reduces the biological and physical stability of liposomes.
Colloidal stability refers to the ability of the liposomes to maintain their size under various storage conditions. Changes in colloidal stability are ascertained by changes in size distribution of liposomes, which can occur as a result of fusion (irreversible pooling of liposomes to form larger liposomes), aggregation and conglomeration (reversible pooling of liposomes to form larger liposomes without fusion). The inherently unstable shape of liposomes (vesicles) is stabilized by different forces: Vander Waals forces among the phospholipids, repulsive forces of the head groups of phospholipids and also short-acting repulsive forces. At a minimum, the liposomal drug products have to be stable for 2 years according to the regulatory agencies. Most important parameters in quality control and characterization of liposomal formulations are size distribution and liposome physical integrity. Physical characterization of sphingomyelin proliposome before and after reconstitution was carried out with different microscopy techniques, as shown in Figure 4 .
In-use stability of liposomes at the clinical site Liposomes used so far for intravesical administration in patients have been sphingomyelin proliposomes, which are reconstituted just before use on the patients. Reconstituted liposomes are liable to conglomerate over time or change in shape, but these changes occurring over short periods of time are generally reversible. In the clinical studies carried out so far, liposomes were administered to patients on the day of reconstitution. Reconstituted liposomes were instilled into the empty bladder of IC/PBS patients through an 8-Fr catheter with 2% lidocaine jelly applied to the catheter tip before insertion. Instilled liposomes are held in the bladder for 30-60 min before the contents are expelled by voiding. Physical, chemical and microbiological studies are carried out to ascertain the in-use period of reconstituted liposomes after which the product should be discarded.
Future directions
Although liposomes have shown their therapeutic potential in the bladder, their site of action and mechanism of action still need to be determined. Further research is required to investigate the depth of tissue penetration in the bladder for the instilled liposomes. Several new research techniques that have recently been discovered can be tried to answer these questions. Stimulated emission depletion microscopy can be combined together with RICS to assess the penetration of intact liposomes beyond urothelium in bladder, while circumventing the diffraction barrier. 77 RICS can be used to measure whether two different fluorophores mixed with deformable and non-deformable liposomes diffuse together in the bladder. The depth of penetration of two fluorophores can be used to check by correlation between the two markers, where a large RICS signal is generated by the diffusion of intact liposomes in the bladder, but the signal is reduced if the liposomes degrade during diffusion and the signal resembles the diffusion of the free dyes.
The surfaces of instilled liposomes in the bladder can be functionalized with ligands for disease proteins in order to allow targeted delivery. Sites of bladder ulcer in IC/PBS are considered to be marked by increased expression of angiogenesis markers, such as vascular endothelial growth factor receptors, VEGFR-1 and VEGFR-2, as well as VEGF co-receptors NRP, NRP1 and NRP2, compared with normal urothelium. 78, 79 Therefore, such sites of increased angiogenesis in the bladder can be targeted with VEGF. 80 Bladder instillation of a targeted fluorescent tracer, an engineered single-chain VEGF labeled with Cy5.5 dye (scVEGF/Cy) showed preferential accumulation at sites of bladder inflammation and in the ganglia. 80 In addition to development for therapeutic purposes, liposomes rendered with stimuli-response properties can be instilled in the bladder for potential diagnostic applications. Liposomes incorporating new imaging agents, such as Gd 3+ and 18 F, have been used for magnetic resonance imaging and nuclear imaging. 81 Magnetic resonance imaging enables real-time monitoring with radio frequency pulses to detect the nuclear spins of water hydrogen atoms. The change of T1 relaxation time of bladder wall tissue after instillation can be a measure of drug delivery. 81 Another option is near-infrared fluorescence imaging for low absorption and scattering of photons within the near-infrared region in animals. 60 The deeper penetration of near-infrared light compared with visible wavelengths allows for the possibility of deeper-tissue imaging, as well as the possibility of long-term imaging without off-target effects of excitation.
Conclusions
Liposomes have been actively researched as a therapeutic and a delivery platform for intravesical route. Liposomes can overcome the restricted permeability of the urothelium, which is a major hindrance for intravesical drug delivery. Some of the obstacles that require special consideration in liposomal therapy are stability issues, scalable manufacturing process, regulatory challenges and cost. Ongoing research affirms the promise of liposome therapy in a clinical setting for treatment-refractory OAB and IC/PBS patients.
